Learning Objectives

• Describe the effects of hemophilia with inhibitors on clinical and economic outcomes as well as quality of life
• Evaluate current and emerging hemophilia therapies for adults with inhibitors
• Implement quality of care recommendations for the treatment of hemophilia with inhibitors
• Employ a collaborative and comprehensive care model, including partnering with HTCs, to optimize clinical and economic outcomes for hemophilia patients with inhibitors
• Utilize the HTC team to provide appropriate care and counsel for patients and their families

Cindy Leissinger, MD Professor of Medicine, Pediatrics & Pathology Chief, Section of Hematology & Medical Oncology Tulane University School of Medicine